ClearBridge Exits ENSG Amid Regulatory and Short-Seller Concerns

ClearBridge Investments' SMID Cap Growth Strategy has exited The Ensign Group (ENSG) amid regulatory and short-seller concerns. Within the healthcare sector, biotechnology and life sciences tools showed positive performance, while provider and select medical technology holdings underperformed. ClearBridge exited ENSG due to regulatory and short-seller-related concerns. ENSG traded at $168.59 in 2026 Q2 and gained %15.67 over the past 52 weeks. The company has a market cap of $9.85 billion and is held by 37 hedge funds. The strategy achieved %24.0 returns but lagged behind the Russell 2500 Growth Index, which rose %24.0. Underperformance was driven by underweighting top AI infrastructure stocks and weaknesses in healthcare and consumer discretionary sectors.

Markets are interpreting this move as a response to rising regulatory risks in healthcare and short-seller pressure. The increased allocation to AI infrastructure stocks aligns with ClearBridge's decision.